The Food and Drug Administration approved revumenib, or Revuforj, from Syndax (SNDX) Pharmaceuticals, a menin inhibitor, for relapsed or refractory acute myeloid leukemia with a susceptible nucleophosmin 1 mutation in adult and pediatric patients 1 year and older who have no satisfactory alternative treatment options.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SNDX:
- Syndax trading halted, news pending
- Syndax assumed with a Buy at H.C. Wainwright
- Strategic Positioning and Competitive Edge: Syndax Pharmaceuticals’ Buy Rating Reinforced by Revuforj’s Milestones in Leukemia Treatment
- Syndax announces updated NCCN Guidelines for AML
- Synopsys downgraded, Oracle upgraded: Wall Street’s top analyst calls